HER-2改变在非小细胞肺癌靶向治疗中的研究进展  

Research progress of HER-2 alterations in targeted therapy of non-small cell lung cancer

作　　者：武明爽 刘佳[1] 杨茂鹏[1] WU Mingshuang;LIU Jia;YANG Maopeng(Department of Medical Oncology,the Affiliated Tumor Hospital of Harbin Medical University,Heilongjiang Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院肿瘤内科,黑龙江哈尔滨150081

出　　处：《现代肿瘤医学》2024年第3期565-569,共5页Journal of Modern Oncology

摘　　要：肺癌是恶性程度和死亡率最高的恶性肿瘤之一,非小细胞肺癌(NSCLC)约占85%。靶向治疗是NSCLC的首选治疗方案。靶向治疗显著改善了ALK、ROS1、BRAF、NTRK、MET和大多数EGFR突变的NSCLC患者的临床结果。但自从发现异常激活的人类表皮生长因子受体2(HER-2)对EGFR抑制剂有耐药性并且其对化疗并不敏感以来,便促进了对HER-2改变的NSCLC患者靶向治疗的深入研究。HER-2改变包括基因突变、扩增和蛋白过表达。HER-2改变的不同类型针对不同的靶向治疗药物,其中HER-2第20外显子突变是NSCLC中具有功能意义的最为重要的驱动突变。本文针对HER-2改变的NSCLC患者的靶向治疗药物:阿法替尼、波齐替尼、吡咯替尼、曲妥珠单抗-美坦新偶联物、溴他替尼等的研究进展进行了详细综述。Lung cancer is one of the malignant tumors with the highest degree of malignancy and mortality.Non-small cell lung cancer(NSCLC)accounts for about 85%.Targeted therapy is the preferred treatment option for NSCLC.Targeted therapies significantly improved clinical outcomes in ALK,ROS1,BRAF,NTRK,MET,and most NSCLC patients with EGFR mutations.However,the discovery that abnormally activated human epidermal growth factor receptor-2(HER-2)is resistant to EGFR inhibitors and is not sensitive to chemotherapy has prompted further research into targeted therapies for HER-2 altered NSCLC patients.HER-2 alterations include gene mutations,amplification and protein overexpression.Different types of HER-2 alterations target different targeted therapies,among which the HER-2 exon 20 mutation is the most important driver mutation with functional significance in NSCLC.In this paper,the research progress of targeted therapies for HER-2 altered NSCLC patients,such as Afatinib,Poziotinib,Pyrotinib,T-DM1 and Tarloxotinib was reviewed in detail.

关 键 词：非小细胞肺癌 人类表皮生长因子受体2 吡咯替尼 曲妥珠单抗-美坦新偶联物 溴他替尼 

分 类 号：R734.2[医药卫生—肿瘤]